We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+12.99%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$725M
AUM Growth
+$66.7M
Cap. Flow
+$14.6M
Cap. Flow %
2.01%
Top 10 Hldgs %
41.88%
Holding
145
New
38
Increased
32
Reduced
27
Closed
36

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$25.1M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$19.4M
3
AMGN icon
Amgen
AMGN
+$17.7M
4
BLUE
bluebird bio
BLUE
+$12.8M
5
VTRS icon
Viatris
VTRS
+$11M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$28.5M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.3M
3
SHPG
Shire pic
SHPG
+$11.3M
4
FOLD
Amicus Therapeutics
FOLD
+$9.93M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.8M

Sector Composition

Rank Sector Weight
1 Healthcare 74.16%
2 Miscellaneous 13.36%
3 Technology 6.12%
4 Financials 1.97%
5 Industrials 1.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CHTR icon
101
Charter Communications
CHTR
$15.3B
$416K 0.06%
1,419
-1,910
-57% -$549K
SITE icon
102
SiteOne Landscape Supply
SITE
$3.89B
$252K 0.03%
3,000
– –
MHK icon
103
Mohawk Industries
MHK
$8.7B
$236K 0.03%
1,100
– –
CISN
104
DELISTED
Cision Ltd. Ordinary Share
CISN
$224K 0.03%
+15,000
New +$211K
SNA icon
105
Snap-on
SNA
$19.2B
$220K 0.03%
1,366
– –
EIDX
106
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$220K 0.03%
+10,828
New +$227K
ULTI
107
DELISTED
Ultimate Software Group Inc
ULTI
$206K 0.03%
800
– –
ZVRA icon
108
Zevra Therapeutics
ZVRA
$703M
$147K 0.02%
+1,414
New +$138K
CHRS icon
109
Coherus Oncology
CHRS
$190M
– –
-270,000
Closed -$2.98M
CMCSA icon
110
Comcast
CMCSA
$81.3B
– –
-10,000
Closed -$342K
EXPE icon
111
Expedia Group
EXPE
$34.2B
– –
-18,900
Closed -$2.09M
KYNB
112
Kyntra Bio
KYNB
$28.7M
– –
-1,591
Closed -$1.84M
LPSN
113
DELISTED
LivePerson
LPSN
– –
-9
Closed -$2K
MGNX icon
114
MacroGenics
MGNX
$263M
– –
-135,000
Closed -$3.4M
MNOV icon
115
MediciNova
MNOV
$170M
– –
-630,838
Closed -$6.45M
NTLA icon
116
Intellia Therapeutics
NTLA
$1.72B
– –
-160,000
Closed -$3.37M
PBYI icon
117
Puma Biotechnology
PBYI
$491M
– –
-60,000
Closed -$4.08M
PRGO icon
118
Perrigo
PRGO
$1.87B
– –
-19,221
Closed -$1.6M
QQQ icon
119
PUT
Invesco QQQ Trust
QQQ
$482B
– –
-80,000
Closed -$12.8M
REGN icon
120
Regeneron Pharmaceuticals
REGN
$81.3B
– –
-41,500
Closed -$14.3M
RGNX icon
121
Regenxbio
RGNX
$542M
– –
-100,000
Closed -$2.98M
SEE
122
DELISTED
Sealed Air
SEE
– –
-4,500
Closed -$193K
SNDX icon
123
Syndax Pharmaceuticals
SNDX
$1.58B
– –
-298,472
Closed -$4.25M
VTVT icon
124
vTv Therapeutics
VTVT
$124M
– –
-7,042
Closed -$1.15M
WSO icon
125
Watsco Inc
WSO
$12.6B
– –
-2,100
Closed -$380K
2 3 4
5
6

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q2 2018 Portfolio in Review

As of Q2 2018, Sphera Funds Management held 145 positions worth $725M, up 10% from $659M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Sphera Funds Management's Q2 2018 filing shows 38 new, 32 increased, 27 reduced and 36 closed positions. Its largest new stake was Gilead Sciences: 355,000 shares worth $25.1M. The largest sale was Celgene Corp, an estimated $28.5M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 77% a quarter earlier, followed by Miscellaneous and Technology.

  • Sphera Funds Management's largest Q2 2018 buy was Gilead Sciences: 355,000 shares worth $25.1M.
  • Sphera Funds Management added most to Viatris in Q2 2018, an estimated $11M increase.
  • Sphera Funds Management's biggest Q2 2018 reduction was Shire pic, cutting an estimated $11.3M.
  • Sphera Funds Management fully exited Celgene Corp in Q2 2018, selling an estimated $28.5M.
  • Sphera Funds Management's ten largest holdings make up 42% of its $725M portfolio in Q2 2018.
  • Sphera Funds Management opened 38 new positions and closed 36 in Q2 2018.
  • Sphera Funds Management's portfolio value rose 10% quarter-over-quarter to $725M.

Based on Sphera Funds Management's 13F filing for Q2 2018, filed 13 Aug 2018.